These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 38950998)

  • 21. The association of amputations and peripheral artery disease in patients with type 2 diabetes mellitus receiving sodium-glucose cotransporter type-2 inhibitors: real-world study.
    Paul SK; Bhatt DL; Montvida O
    Eur Heart J; 2021 May; 42(18):1728-1738. PubMed ID: 33289789
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cardiovascular Outcomes Among Patients with Type 2 Diabetes Newly Initiated on Sodium-Glucose Cotransporter-2 Inhibitors, Glucagon-Like Peptide-1 Receptor Agonists, and Other Antidiabetic Medications.
    Pineda ED; Liao IC; Godley PJ; Michel JB; Rascati KL
    J Manag Care Spec Pharm; 2020 May; 26(5):610-618. PubMed ID: 32347181
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cardiovascular outcomes associated with prescription of sodium-glucose co-transporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors in patients with diabetes and chronic kidney disease.
    Rhee JJ; Han J; Montez-Rath ME; Kim SH; Cullen MR; Stafford RS; Winkelmayer WC; Chertow GM
    Diabetes Obes Metab; 2022 May; 24(5):928-937. PubMed ID: 35118793
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparative effectiveness of second line oral antidiabetic treatments among people with type 2 diabetes mellitus: emulation of a target trial using routinely collected health data.
    Bidulka P; Lugo-Palacios DG; Carroll O; O'Neill S; Adler AI; Basu A; Silverwood RJ; Bartlett JW; Nitsch D; Charlton P; Briggs AH; Smeeth L; Douglas IJ; Khunti K; Grieve R
    BMJ; 2024 May; 385():e077097. PubMed ID: 38719492
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Association Between Sodium-Glucose Cotransporter 2 Inhibitors and Lower Extremity Amputation Among Patients With Type 2 Diabetes.
    Chang HY; Singh S; Mansour O; Baksh S; Alexander GC
    JAMA Intern Med; 2018 Sep; 178(9):1190-1198. PubMed ID: 30105373
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Diabetes medication regimens and patient clinical characteristics in the national patient-centered clinical research network, PCORnet.
    Bachmann KN; Roumie CL; Wiese AD; Grijalva CG; Buse JB; Bradford R; Zalimeni EO; Knoepp P; Dard S; Morris HL; Donahoo WT; Fanous N; Fonseca V; Katalenich B; Choi S; Louzao D; O'Brien E; Cook MM; Rothman RL; Chakkalakal RJ
    Pharmacol Res Perspect; 2020 Oct; 8(5):e00637. PubMed ID: 32881317
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical inertia among patients with type 2 diabetes mellitus treated with DPP-4i and/or SGLT-2i.
    Lanzinger S; Schmid SM; Welp R; Zimmermann A; Fasching P; Wagner S; Holl RW
    Diabetes Res Clin Pract; 2018 Dec; 146():162-171. PubMed ID: 30367902
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Two years with GIOIA 'Effects of gliflozins and gliptins on markers of cardiovascular damage in type 2 diabetes': A prospective, multicentre, quasi-experimental study on sodium-glucose cotransporter 2 and dipeptidyl peptidase-4 inhibitors in diabetes clinical practice.
    Longo M; Caruso P; Scappaticcio L; Maiorino MI; Bellastella G; Capuano A; Esposito K; Giugliano D
    Diabetes Obes Metab; 2024 Apr; 26(4):1492-1501. PubMed ID: 38234208
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparative cardiovascular safety of GLP-1 receptor agonists versus other glucose-lowering agents in real-world patients with type 2 diabetes: a nationwide population-based cohort study.
    Yang CT; Yang CY; Ou HT; Kuo S
    Cardiovasc Diabetol; 2020 Jun; 19(1):83. PubMed ID: 32534570
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of DPP-4 inhibitors, GLP-1 receptor agonists, SGLT-2 inhibitors and sulphonylureas on mortality, cardiovascular and renal outcomes in type 2 diabetes: A network meta-analyses-driven approach.
    Brønden A; Christensen MB; Glintborg D; Snorgaard O; Kofoed-Enevoldsen A; Madsen GK; Toft K; Kristensen JK; Højlund K; Hansen TK; Søndergaard E; Hansen KB
    Diabet Med; 2023 Aug; 40(8):e15157. PubMed ID: 37249579
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Use of Sodium-Glucose Co-Transporter 2 Inhibitors in Patients With Type 2 Diabetes and the Incidence of Retinal Vein Occlusion in Taiwan.
    Tsai HR; Lin YJ; Yeh JI; Lin SM; Liu PP; Chang YC; Lee YC; Loh CH; Huang HK
    Invest Ophthalmol Vis Sci; 2024 Jun; 65(6):19. PubMed ID: 38864813
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Application of new glucose lowering drugs: DPP-4 inhibitors, GLP-1 receptor agonists and SGLT-2 inhibitors].
    Verburg AFE; van den Donk M; Wiersma T
    Ned Tijdschr Geneeskd; 2019 Jan; 163():. PubMed ID: 30676706
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cardiovascular Events Associated With SGLT-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL 2 Study.
    Kosiborod M; Lam CSP; Kohsaka S; Kim DJ; Karasik A; Shaw J; Tangri N; Goh SY; Thuresson M; Chen H; Surmont F; Hammar N; Fenici P;
    J Am Coll Cardiol; 2018 Jun; 71(23):2628-2639. PubMed ID: 29540325
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prescription Trends for the Antidiabetic Agents Used to Treat Type 2 Diabetes Mellitus in Japan from 2012-2020: a Time-Series Analysis.
    Iketani R; Imai S
    Biol Pharm Bull; 2023; 46(4):592-598. PubMed ID: 37005303
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Novel glucose lowering agents are associated with a lower risk of cardiovascular and adverse events in type 2 diabetes: A population based analysis.
    Elharram M; Moura CS; Abrahamowicz M; Bernatsky S; Behlouli H; Raparelli V; Pilote L
    Int J Cardiol; 2020 Jul; 310():147-154. PubMed ID: 32303419
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of Glucagon-Like Peptide-1 Receptor Agonists, Sodium-Glucose Cotransporter-2 Inhibitors, and Their Combination on Endothelial Glycocalyx, Arterial Function, and Myocardial Work Index in Patients With Type 2 Diabetes Mellitus After 12-Month Treatment.
    Ikonomidis I; Pavlidis G; Thymis J; Birba D; Kalogeris A; Kousathana F; Kountouri A; Balampanis K; Parissis J; Andreadou I; Katogiannis K; Dimitriadis G; Bamias A; Iliodromitis E; Lambadiari V
    J Am Heart Assoc; 2020 May; 9(9):e015716. PubMed ID: 32326806
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prescription Patterns of Novel Antihyperglycemic Medications.
    Ali AS; Khan M; Ortega D; Jaffery S; Lamerato LE; Budzynska K
    J Am Board Fam Med; 2022; 35(2):255-264. PubMed ID: 35379713
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Do GLP-1RAs and SGLT-2is reduce cardiovascular events in black patients with type 2 diabetes? A systematic review and meta-analysis.
    Mishriky BM; Powell JR; Wittwer JA; Chu JX; Sewell KA; Wu Q; Cummings DM
    Diabetes Obes Metab; 2019 Oct; 21(10):2274-2283. PubMed ID: 31168889
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Real-world characteristics, modern antidiabetic treatment patterns, and comorbidities of patients with type 2 diabetes in central and Eastern Europe: retrospective cross-sectional and longitudinal evaluations in the CORDIALLY
    Prázný M; Suplotova L; Gumprecht J; Kamenov Z; Fülöp T; Medvedchikov A; Rosenzweig D; Aleksandric M
    Cardiovasc Diabetol; 2022 Oct; 21(1):203. PubMed ID: 36209118
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Drug utilisation study of antidiabetic medication during 2012-2019 in Romania.
    Bucsa C; Farcas A; Iaru I; Mogosan C; Rusu A
    Int J Clin Pract; 2021 Nov; 75(11):e14770. PubMed ID: 34473890
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.